

PATENT Attorney Docket No. LEX-010C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Gillies et al.

SERIAL NO.:

10/603,064

GROUP NO.:

1646

FILING DATE:

June 24, 2003

EXAMINER:

P. Mertz

TITLE:

Multiple Cytokine Protein Complexes

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 8th day of March, 2005.

Brenda L. MacLean

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith are:

- 1. Transmittal Form (1 page);
- 2. Power of Attorney by Assignee of Entire Interest/Revocation of Prior Powers and New Power of Attorney (1 page);
- 3. and a return receipt postcard.

	OIPE						
MAR 1 0 2005 E TRANSMITTAL FORM			Application Serial Number		T	10/603,064	
			Filing Date	June		June 24, 2003	
			First Named	First Named Inventor C		Gillies	
			Group Art Unit		\top	1646	
			Examiner Name		+	P. Mertz	
			Attorney Docket No.		1	LEX-010C1	
·			Confirmation	on No.	\top	8576	
					1		
ENCLOSURES (check all that apply)							
☐ Fe	e Transmittal Form		Copy of Notic Parts of Applie	e to File Missing cation		Notice of Appeal to Board of Patent Appeals and Interferences	
	☐ Check Attached ☐ Copy of Fee Transmittal Form		Formal Drawin	ng(s)		Appeal Brief (in triplicate)	
	Amendment/Response		Request For C Examination (Status Inquiry	
	☐ Preliminary ☐ After Final		Transmittal			Return Receipt Postcard	
P	☐ Affidavits/declaration(s) ☐ Letter to Official ☐ Draftsperson	Ø				•	
	including Drawings				_	_	
	[Total Sheets]		Terminal Disc	laimer		Certificate of Facsimile Transmission under 37 C.F.R. 1.8	
	Petition for Extension of Time			laration and Power r Utility or Design ation			
	Information Disclosure Statement		Small Entity S	tatement			
	Form PTO-1449 Copies of IDS Citations		CD(s) for larg	e table or computer			
	Certified Copy of Priority Document(s)		Amendment After Allow		: :		
		<u> </u>	Request for Co	ertificate of			
	Sequence Listing submission Paper Copy/CD		Correction Certificate	e of Correction (in			
	☐ Computer Readable Copy ☐ Statement verifying		duplicate)	, o. co. so. o. (:		
identity of above CORRESPONDENCE ADDRESS				SIGNATURE BLO		K	
Direct all correspondence to: Patent Administrator					J ()	Respectfully submitted,	
Kirkpatrick & Lockhart Nicholson Graham LLP 75 State Street Boston, MA 02109-1808 Tel. No.: (617) 261-3100 Fax No.: (617) 261-3175				Date: March 8, 2005 Reg. No. 48,645 Tel. No.: (617) 261-3169 Fax No.: (617) 261-3175			



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTORS:

Gillies et al.

ASSIGNEE:

EMD Lexigen Research Center Corp.

SERIAL NO.:

10/603,064

FILING DATE:

June 24, 2003

TITLE:

Multiple Cytokine Protein Complexes

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

<u>POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST</u> REVOCATION OF PRIOR POWERS AND NEW POWER OF ATTORNEY

Sir:

As an authorized representative of the assignee of record of the entire right, title, and interest in the above-identified patent application, I hereby revoke all powers of attorney previously given and hereby appoint the registered patent practitioners associated with **Customer Number 022832** to prosecute and transact all business in the U.S. Patent and Trademark Office connected therewith.

Please direct all correspondence for the above-identified patent application to the address associated with the above Customer Number.

The assignee of record of the entire right, title, and interest in the above-identified patent application is EMD Lexigen Research Center Corp., by virtue of the chain of title from the inventors of the above-identified patent application to the current assignee, as shown below:

By assignment on October 11, 2000, from Stephen D. Gillies and Kin-Ming Lo to Lexigen Pharmaceuticals Corp., recorded in the U. S. Patent and Trademark Office on November 5, 2003, at Reel No.: 014663, Frame No.: 0092; and

By a corporate change of name from Lexigen Pharmaceuticals Corp. to EMD Lexigen Research Center Corp. on May 30, 2002, recorded in the U. S. Patent and Trademark Office on December 19, 2003, at Reel No.: 014815, Frame No.: 0751.

Respectfully submitted,

Dated: $\frac{3}{3}/2005$

Stephen D. Gillies, Ph.D.

President

EMD Lexigen Research Center Corp.

Bedford Campus

45A Middlesex Turnpike

Billerica, MA 01821